Unique

our projects

The project portfolio of Xlife Sciences AG is based on four pillars: technology platforms, biotech and therapies, medical technology and artificial intelligence. Our co-investors benefit from our unique selling proposition. In addition, our broad project portfolio offers adequate risk diversification.

alytas therapeutics GmbH

Biotech and Therapies

alytas therapeutics GmbH is a spin-off of the University of Jena with the aim to develop novel immunological therapy concepts for the treatment of worldwide increasing pathological obesity, a condition with so far unmet medical need and one of the three largest global social burdens caused by humans.

Learn more

clyxop devices UG

Biotech and Therapies

Based on biocellulose, clyxop devices UG develops tubes that can be used as a bridging agent in cases of damage to hollow organs and stimulate tissue regeneration.

Learn more

inflamed pharma GmbH

Biotech and Therapies

inflamed pharma GmbH produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients applied in innovative therapies for human and veterinary medicine.

Learn more

Lysatpharma GmbH

Biotech and Therapies

Lysatpharma GmbH is an innovation-based startup company in the field of biotechnological research and development.

Learn more

Synimmune GmbH

Biotech and Therapies

Synimmune GmbH is a biotechnology company dedicated to the development of innovative and effective mono-and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies.

Learn more

Sign up for our newsletter

We regularly report on the business development of Xlife Sciences AG and our project companies.